Additionally, regulatory agencies are moving toward requiring that companies provide comprehensive lists of ingredients and credible scientific evidence to substantiate their product claims
rats in the osteoporotic group showed a significant decrease in estradiol levels by 72.64% when compared to the control group, and the other treated groups (alendronate group, semaglutide 150, and semaglutide 300) showed a significant decrease by 71.3%, 70.15%, and 72.1%, respectively, when compared to the control group
PT-141 was deemed safe enough to be granted approval by the US FDA in 2019 and has not been found to cause serious adverse events or side effects at a statistically significant rate [10]
Topol reported that, prior to the reports publication, scientists from the billion-dollar drug company requested that the information be kept from the public
These include unexplained fatigue or energy changes, significant mood alterations, palpitations or irregular heartbeat, increased sensitivity to heat or cold, changes in bowel habits beyond expected medication side effects, unexplained hair loss, or skin changes
